Clever Leaves Holdings Inc.
Healthcare · Pharmaceutical Preparations · A1 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
| Revenue | $17.4M | $16.4M | $15.4M | $12.1M | $7.8M |
| Operating income | −$15.6M | −$46.9M | −$57.2M | −$28.5M | −$36.5M |
| Net income | −$17.9M | −$66.2M | −$45.7M | −$25.9M | −$39.5M |
| Total assets | $31.2M | $52.1M | $116.2M | $165.9M | $95.7M |
| Total liabilities | $7.0M | $11.7M | $43.4M | $70.6M | $45.5M |
| Equity | $24.2M | $40.4M | $72.8M | $95.3M | $50.2M |
| EPS (diluted) | $-11.42 | $-51.70 | $-1.78 | $-3.34 | — |
| Shares out. | 1.7M | 1.5M | 26.6M | 24.9M | 8.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −89.5%
- Net margin
- −102.8%
- Return on equity
- −73.9%
- Return on assets
- −57.3%
- Return on capital (ROCE)
- −61.3%
- Liabilities / assets
- 22.5%
- Debt / equity
- 0.29×
- Book value / share
- $14.02
- Revenue growth (YoY)
- 6.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -18.77distress
- Accruals / assets
- −20.5%clean
- Beneish M-Score
- -3.92normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Regulation FD disclosureApr 26, 2024
- Terminated a material agreementApr 17, 2024
- Results of operationsApr 1, 2024
- Entered a material agreement · Completed an acquisition or dispositionMar 27, 2024
- Entered a material agreementFeb 1, 2024
- Entered a material agreementDec 20, 2023
- Results of operationsNov 9, 2023
- Entered a material agreementOct 23, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 3OWNERSHIP DOCUMENTMay 21, 2024
- SC 13D/AMay 21, 2024
- 15-12GFORM 15-12GMay 16, 2024
- SC 13DMay 15, 2024
- EFFECTMay 8, 2024
- S-8 POSREGISTRATION STATEMENTMay 6, 2024
- S-8 POSREGISTRATION STATEMENTMay 6, 2024
- S-8 POSREGISTRATION STATEMENTMay 6, 2024
- POS AMPOST-EFFECTIVE AMENDMENT NO. 5 TO FORM S-1May 6, 2024
- 25FORM 25May 6, 2024
- 8-KCURRENT REPORTApr 26, 2024
- EFFECTApr 22, 2024
- AWAMENDMENT WITHDRAWALApr 19, 2024
- 8-KApr 17, 2024
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Apr 16, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.